Search

Your search keyword '"Pohlreich, David"' showing total 133 results
Start Over Author "Pohlreich, David"
133 results on '"Pohlreich, David"'

2. Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

Author

Sureda, Anna, Chabannon, Christian, Masszi, Tamás, Pohlreich, David, Scheid, Christof, Thieblemont, Catherine, Wahlin, Björn E., Sakellari, Ioanna, Russell, Nigel, Janikova, Andrea, Dabrowska-Iwanicka, Anna, Touzeau, Cyrille, Esquirol, Albert, Jantunen, Esa, van der Werf, Steffie, Bosman, Paul, Boumendil, Ariane, Liu, Qianying, Celanovic, Marina, Montoto, Silvia, and Dreger, Peter

Published
2020
Full Text
View/download PDF

3. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Author

Morris, Curly, Chabannon, Christian, Masszi, Tamas, Russell, Nigel, Nahi, Hareth, Kobbe, Guido, Krejci, Marta, Auner, Holger W., Pohlreich, David, Hayden, Patrick, Basak, Grzegorz W., Lenhoff, Stig, Schaap, Nicolaas, van Biezen, Anja, Knol, Cora, Iacobelli, Simona, Liu, Qianying, Celanovic, Marina, Garderet, Laurent, and Kröger, Nicolaus

Published
2020
Full Text
View/download PDF

4. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Author

Acar, Kadir, Afanasyev, Boris, Alonso Alonso, Aránzazu, Anttila, Veli-Jukka, Barba Suñol, Pere, Blesing, Norbert, Comeau, Terrance, del Campo, Teresa, Disperati, Patricia, Eek, Richard, Eom, HyeonSeok, Gaidano, Gianluca, Grosicki, Sebastian, Guillaume, Thierry, Homenda, Wojciech, Hwang, William, Ilyin, Nikolay, Johnston, Anna, Kim, Seok Jin, Kuo, Ching-Yuan, Kuvshinov, Aleksey, Lee, Dong-Gun, Lee, Jae Hoon, Lee, Je-Jung, Lepretre, Stephane, Lie, Albert Kwok-Wai, Lucchesi, Alessandro, Masood, Ahmed, Mir, Naheed, Miranda Castillo, Anna Carolina, Mullane, Kathleen, Myasnikov, Alexandr, Oña Navarrete, Raquel, Pauksens, Karlis, Peniket, Andrew, Perez de Oteyza, Jaime, Pohlreich, David, Pullon, Humphrey, Quittet, Philippe, Rodon, Philippe, Rombo, Lars, Samoylova, Olga, Sanmartin Berglund, Johan, Schattner, Ariah, Selleslag, Dominik, Sinisalo, Marjatta, Sultan, Faisal, Theunissen, Koen, Turner, Paul, Wang, Po-Nan, Yáñez San Segundo, Lucrecia, Young, Jo-Anne, Zachee, Pierre, Zaja, Francesco, Dagnew, Alemnew F, Ilhan, Osman, Lee, Won-Sik, Woszczyk, Dariusz, Kwak, Jae-Yong, Bowcock, Stella, Sohn, Sang Kyun, Rodriguez Macías, Gabriela, Chiou, Tzeon-Jye, Quiel, Dimas, Aoun, Mickael, Navarro Matilla, Maria Belen, de la Serna, Javier, Milliken, Samuel, Murphy, John, McNeil, Shelly A, Salaun, Bruno, Di Paolo, Emmanuel, Campora, Laura, López-Fauqued, Marta, El Idrissi, Mohamed, Schuind, Anne, Heineman, Thomas C, Van den Steen, Peter, and Oostvogels, Lidia

Published
2019
Full Text
View/download PDF

5. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

Author

Garderet, Laurent, Iacobelli, Simona, Koster, Linda, Goldschmidt, Hartmut, Johansson, Jan-Erik, Bourhis, Jean Henri, Krejci, Marta, Leleu, Xavier, Potter, Michael, Blaise, Didier, Koenecke, Christian, Peschel, Christian, Radocha, Jakub, Metzner, Bernd, Lenain, Pascal, Schäfer-Eckart, Kerstin, Pohlreich, David, Grasso, Mariella, Caillot, Denis, Einsele, Herman, Ladetto, Marco, Schönland, Stefan, and Kröger, Nicolaus

Published
2018
Full Text
View/download PDF

6. Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation

Author

Avivi, Irit, Boumendil, Ariane, Finel, Hervé, Nagler, Arnon, de Sousa, Aïda Botelho, Santasusana, Josep Maria Ribera, Vandenberghe, Elizabeth, Afanasyev, Boris, Bordessoule, Dominique, Moraleda, José Maria, Garcia, Eulogio Conde, Pohlreich, David, Garcia, Gonzalo Gutiérrez, Thomson, Kirsty, Or, Reuven, Beelen, Dietrich, Zuffa, Eliana, Giebel, Sebastian, Berthou, Christian, Salles, Gilles, Melpignano, Angela, Montoto, Silvia, and Dreger, Peter

Published
2018
Full Text
View/download PDF

13. Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT

Author

Pytlík, Robert, primary, Vacková, Blanka, additional, Konířová, Eva, additional, Trnková, Marie, additional, Blahovcová, Petra, additional, Pohlreich, David, additional, Polgárová, Kamila, additional, Klener, Pavel, additional, Benešová, Kateřina, additional, Kopečková, Kateřina, additional, Pirnos, Jan, additional, and Trněný, Marek, additional

Published
2020
Full Text
View/download PDF

16. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

Author

Bastidas, Adriana de la Serna, Javier El Idrissi, Mohamed and Oostvogels, Lidia Quittet, Philippe Lopez-Jimenez, Javier and Vural, Filiz Pohlreich, David Zuckerman, Tsila Issa, Nicolas C. Gaidano, Gianluca Lee, Je-Jung Abhyankar, Sunil and Solano, Carlos Perez de Oteyza, Jaime Satlin, Michael J. and Schwartz, Stefan Campins, Magda Rocci, Alberto Llamas, Carlos Vallejo Lee, Dong-Gun Tan, Sen Mui Johnston, Anna M. and Grigg, Andrew Boeckh, Michael J. Campora, Laura and Lopez-Fauqued, Marta Heineman, Thomas C. Stadtmauer, Edward A. and Sullivan, Keith M. Alonso Alonso, Aranzazu Anagnostopoulos, Achilles Andreadis, Charalambos (Babis) Angelopoulou, Maria and Anttila, Veli-Jukka Aoun, Mickael Barista, Ibrahim Berkahn, Leanne Bloor, Adrian J. C. Broady, Raewyn Brossart, Peter and Buadi, Francis K. Bulabois, Claude-Eric Cantin, Guy and Cellini, Claudia Chandrasekar, Pranatharthi Haran Chauncey, Thomas Cuneo, Antonio Dadwal, Sanjeet Singh Dickinson, Michael Eom, HyeonSeok Esquirol Sanfeliu, Albert Ferra Coll, Christelle Flomenberg, Phyllis R. Pilar Gonzalez-Rodriguez, Ana and Gottlieb, David J. Grisariu, Sigal Guenther, Andreas and Gutman, Jonathan Hahn, Uwe Heinz, Werner J. Heras, Inmaculada Ikeda, Takashi Jarque, Isidro Karthaus, Meinolf and Kerre, Tessa Kiani, Alexander Klein, Andreas K. Kofla, Grzegorz Kryuchkova, Irina V. Kuo, Ching-Yuan Kuruvilla, John Kuvshinov, Aleksey Kwak, Jae-Yong Lee, Jae Hoon and Lepretre, Stephane Lie, Albert Kwok-Wai Lucchesi, Alessandro and Maertens, Johan Marijt, Erik W. A. Martinez Munoz, Carmen and Michieli, Mariagrazia Milliken, Samuel T. Milpied, Noel and Monserrat Coll, Jorge Mossad, Sherif Beniameen Murphy, John and Navarro Matilla, Maria Belen Novak, Jan Olney, Harold J. Ona Navarrete, Raquel Pascual Cascon, Maria Jesus Peniket, Andy and Penka, Ganeva Piatkowska-Jakubas, Beata Polo Zarzuela, Marta and Quiel, Dimas Rowley, Scott D. Sabry, Waleed Salmi, Tommi Mikael Selleslag, Dominik L. D. Shea, Thomas C. Silling, Gerda Sinisalo, Ulla Marjatta Sohn, Sang Kyun Staib, Peter and Szer, Jeff Theunissen, Koen Topcuoglu, Pervin Tyurina, Natalya G. Uvarov, Mikhail Wahid, Fadilah S. Abdul Yanez San Segundo, Lucrecia Yegin, Zeynep Arzu Yeh, Su-Peng Yip, Sze-Fai Yoon, Sung Soo Young, Jo-Anne H. Zachee, Pierre and Zaja, Francesco ZOE-HSCT Study Grp Collaborators

Abstract

IMPORTANCE Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. OBJECTIVE To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. INTERVENTIONS Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n=922) or placebo (n=924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. MAIN OUTCOMES AND MEASURES The primary end point was occurrence of confirmed herpes zoster cases. RESULTS Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P

Published
2019

17. Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

Author

Sureda, Anna, primary, Chabannon, Christian, additional, Masszi, Tamás, additional, Pohlreich, David, additional, Scheid, Christof, additional, Thieblemont, Catherine, additional, Wahlin, Björn E., additional, Sakellari, Ioanna, additional, Russell, Nigel, additional, Janikova, Andrea, additional, Dabrowska-Iwanicka, Anna, additional, Touzeau, Cyrille, additional, Esquirol, Albert, additional, Jantunen, Esa, additional, van der Werf, Steffie, additional, Bosman, Paul, additional, Boumendil, Ariane, additional, Liu, Qianying, additional, Celanovic, Marina, additional, Montoto, Silvia, additional, and Dreger, Peter, additional

Published
2019
Full Text
View/download PDF

18. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Author

Morris, Curly, primary, Chabannon, Christian, additional, Masszi, Tamas, additional, Russell, Nigel, additional, Nahi, Hareth, additional, Kobbe, Guido, additional, Krejci, Marta, additional, Auner, Holger W., additional, Pohlreich, David, additional, Hayden, Patrick, additional, Basak, Grzegorz W., additional, Lenhoff, Stig, additional, Schaap, Nicolaas, additional, van Biezen, Anja, additional, Knol, Cora, additional, Iacobelli, Simona, additional, Liu, Qianying, additional, Celanovic, Marina, additional, Garderet, Laurent, additional, and Kröger, Nicolaus, additional

Published
2019
Full Text
View/download PDF

19. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Author

Dagnew, Alemnew F, primary, Ilhan, Osman, additional, Lee, Won-Sik, additional, Woszczyk, Dariusz, additional, Kwak, Jae-Yong, additional, Bowcock, Stella, additional, Sohn, Sang Kyun, additional, Rodriguez Macías, Gabriela, additional, Chiou, Tzeon-Jye, additional, Quiel, Dimas, additional, Aoun, Mickael, additional, Navarro Matilla, Maria Belen, additional, de la Serna, Javier, additional, Milliken, Samuel, additional, Murphy, John, additional, McNeil, Shelly A, additional, Salaun, Bruno, additional, Di Paolo, Emmanuel, additional, Campora, Laura, additional, López-Fauqued, Marta, additional, El Idrissi, Mohamed, additional, Schuind, Anne, additional, Heineman, Thomas C, additional, Van den Steen, Peter, additional, Oostvogels, Lidia, additional, Acar, Kadir, additional, Afanasyev, Boris, additional, Alonso Alonso, Aránzazu, additional, Anttila, Veli-Jukka, additional, Barba Suñol, Pere, additional, Blesing, Norbert, additional, Comeau, Terrance, additional, del Campo, Teresa, additional, Disperati, Patricia, additional, Eek, Richard, additional, Eom, HyeonSeok, additional, Gaidano, Gianluca, additional, Grosicki, Sebastian, additional, Guillaume, Thierry, additional, Homenda, Wojciech, additional, Hwang, William, additional, Ilyin, Nikolay, additional, Johnston, Anna, additional, Kim, Seok Jin, additional, Kuo, Ching-Yuan, additional, Kuvshinov, Aleksey, additional, Lee, Dong-Gun, additional, Lee, Jae Hoon, additional, Lee, Je-Jung, additional, Lepretre, Stephane, additional, Lie, Albert Kwok-Wai, additional, Lucchesi, Alessandro, additional, Masood, Ahmed, additional, Mir, Naheed, additional, Miranda Castillo, Anna Carolina, additional, Mullane, Kathleen, additional, Myasnikov, Alexandr, additional, Oña Navarrete, Raquel, additional, Pauksens, Karlis, additional, Peniket, Andrew, additional, Perez de Oteyza, Jaime, additional, Pohlreich, David, additional, Pullon, Humphrey, additional, Quittet, Philippe, additional, Rodon, Philippe, additional, Rombo, Lars, additional, Samoylova, Olga, additional, Sanmartin Berglund, Johan, additional, Schattner, Ariah, additional, Selleslag, Dominik, additional, Sinisalo, Marjatta, additional, Sultan, Faisal, additional, Theunissen, Koen, additional, Turner, Paul, additional, Wang, Po-Nan, additional, Yáñez San Segundo, Lucrecia, additional, Young, Jo-Anne, additional, Zachee, Pierre, additional, and Zaja, Francesco, additional

Published
2019
Full Text
View/download PDF

20. Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Author

Auner, Holger W., Iacobelli, Simona, Sbianchi, Giulia, Knol-Bout, Cora, Blaise, Didier, Russell, Nigel H., Apperley, Jane F., Pohlreich, David, Browne, Paul V., Kobbe, Guido, Isaksson, Cecilia, Lenhoff, Stig, Scheid, Christof, Touzeau, Cyrille, Jantunen, Esa, Anagnostopoulos, Achilles, Yakoub-Agha, Ibrahim, Tanase, Alina, Schaap, Nicolaas, Wiktor-Jedrzejczak, Wieslaw, Krejci, Marta, Schoenland, Stefan O., Morris, Curly, Garderet, Laurent, Kroeger, Nicolaus, Auner, Holger W., Iacobelli, Simona, Sbianchi, Giulia, Knol-Bout, Cora, Blaise, Didier, Russell, Nigel H., Apperley, Jane F., Pohlreich, David, Browne, Paul V., Kobbe, Guido, Isaksson, Cecilia, Lenhoff, Stig, Scheid, Christof, Touzeau, Cyrille, Jantunen, Esa, Anagnostopoulos, Achilles, Yakoub-Agha, Ibrahim, Tanase, Alina, Schaap, Nicolaas, Wiktor-Jedrzejczak, Wieslaw, Krejci, Marta, Schoenland, Stefan O., Morris, Curly, Garderet, Laurent, and Kroeger, Nicolaus

Abstract

Melphalan at a dose of 200 mg/m(2) is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m(2) is often used in clinical practice in patients perceived to be at risk of excess toxicity. To determine whether melphalan 200 mg/m(2) and melphalan 140 mg/m(2) are equally effective and tolerable in clinically relevant patient subgroups we analyzed 1964 first single autologous transplantation episodes using a series of Cox proportional-hazards models. Overall survival, progression-free survival, cumulative incidence of relapse, non-relapse mortality, hematopoietic recovery and second primary malignancy rates were not significantly different between the melphalan 140 mg/m(2) (n=245) and melphalan 200 mg/m(2) (n=1719) groups. Multivariable subgroup analysis showed that disease status at transplantation interacted with overall survival, progression-free survival, and cumulative incidence of relapse, with a significant advantage associated with melphalan 200 mg/m(2) in patients transplanted in less than partial response (adjusted hazard ratios for melphalan 200 mg/m(2) versus melphalan 140 mg/m(2): 0.5, 0.54, and 0.56). In contrast, transplantation in very good partial or complete response significantly favored melphalan 140 mg/m(2) for overall survival (adjusted hazard ratio: 2.02). Age, renal function, prior proteasome inhibitor treatment, gender, or Karnofsky score did not interact with overall/progression-free survival or relapse rate in the melphalan dose groups. There were no significant survival or relapse rate differences between melphalan 200 mg/m(2) and melphalan 140 mg/m(2) patients with high-risk or standard-risk chromosomal abnormalities. In conclusion, remission status at the time of transplantation may favor the use of melphalan 200 mg/m(2) or melphalan 140 mg/m(2) for key transplant outcomes (NCT01362972).

Published
2018

21. Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients with Lymphoma Receiving Plerixafor

Author

Sureda, Anna, Chabannon, Christian, Masszi, Tamas, Pohlreich, David, Scheid, Christof, Thieblemont, Catherine, Wahlin, Bjorn E., Sakellari, Ioanna, Russell, Nigel, Janikova, Andrea, Dabrowska-Iwanicka, Anna, Touzeau, Cyrille, Esquirol, Albert, Jantunen, Esa, van der Werf, Steffie, Bosman, Paul, Boumendil, Ariane, Liu, Qianying, Celanovic, Marina, Montoto, Silvia, Dreger, Peter, Sureda, Anna, Chabannon, Christian, Masszi, Tamas, Pohlreich, David, Scheid, Christof, Thieblemont, Catherine, Wahlin, Bjorn E., Sakellari, Ioanna, Russell, Nigel, Janikova, Andrea, Dabrowska-Iwanicka, Anna, Touzeau, Cyrille, Esquirol, Albert, Jantunen, Esa, van der Werf, Steffie, Bosman, Paul, Boumendil, Ariane, Liu, Qianying, Celanovic, Marina, Montoto, Silvia, and Dreger, Peter

Published
2018

22. High‐dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL‐GITMO

Author

Avivi, Irit, primary, Arcaini, Luca, additional, Ferretti, Virginia V., additional, Boumendil, Ariane, additional, Finel, Hervé, additional, Milone, Giuseppe, additional, Zaja, Francesco, additional, Liliana, Devizzi, additional, Musso, Maurizio, additional, Didier, Blaise, additional, Bachy, Emmanuel, additional, Wattad, Mohammed, additional, Nicolas‐Virelizier, Emmanuelle, additional, Gramatzki, Martin, additional, Bourhis, Jean‐Henri, additional, Caillot, Denis, additional, Haenel, Anette, additional, Held, Gerhard, additional, Thieblemont, Catherine, additional, Jindra, Pavel, additional, Pohlreich, David, additional, Guilhot, François, additional, Kroschinsky, Frank, additional, Wahlin, Björn, additional, Scheid, Christof, additional, Ifrah, Norbert, additional, Berthou, Christian, additional, Dreger, Peter, additional, Montoto, Silvia, additional, and Conconi, Annarita, additional

Published
2018
Full Text
View/download PDF

23. Melphalan 140 mg/m 2 or 200 mg/m 2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Author

Auner, Holger W., primary, Iacobelli, Simona, additional, Sbianchi, Giulia, additional, Knol-Bout, Cora, additional, Blaise, Didier, additional, Russell, Nigel H., additional, Apperley, Jane F., additional, Pohlreich, David, additional, Browne, Paul V., additional, Kobbe, Guido, additional, Isaksson, Cecilia, additional, Lenhoff, Stig, additional, Scheid, Christof, additional, Touzeau, Cyrille, additional, Jantunen, Esa, additional, Anagnostopoulos, Achilles, additional, Yakoub-Agha, Ibrahim, additional, Tanase, Alina, additional, Schaap, Nicolaas, additional, Wiktor-Jedrzejczak, Wieslaw, additional, Krejci, Marta, additional, Schönland, Stefan O., additional, Morris, Curly, additional, Garderet, Laurent, additional, and Kröger, Nicolaus, additional

Published
2017
Full Text
View/download PDF

24. Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma

Author

Garderet, Laurent, primary, Iacobelli, Simona, additional, van Biezen, Anja, additional, Koster, Linda, additional, Dreger, Peter, additional, Johansson, Jan Erik, additional, Leleu, Xavier, additional, Potter, Michael, additional, Mayer, Jiri, additional, Peschel, Christian, additional, Zak, Pavel, additional, Ganser, Arnold, additional, Metzner, Bernd, additional, Saglio, Giuseppe, additional, Schafer-Eckart, Kerstin, additional, Pohlreich, David, additional, Tilly, Herve, additional, Grasso, Mariella, additional, Caillot, Denis, additional, Einsele, Herman, additional, Sengeloev, Henrik, additional, Bron, Dominique, additional, Ciceri, Fabio, additional, Schoenland, Stefan, additional, and kroger, Nicolaus, additional

Published
2017
Full Text
View/download PDF

25. Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma

Author

Garderet, Laurent, primary, Iacobelli, Simona, additional, van Biezen, Anja, additional, Koster, Linda, additional, Dreger, Peter, additional, Johansson, Jan-Erik, additional, Leleu, Xavier, additional, Potter, Michael, additional, Krejci, Marta, additional, Peschel, Christian, additional, Radocha, Jakub, additional, Ganser, Arnold, additional, Metzner, Bernd, additional, Paoli, Nicoli, additional, Schäfer-Eckart, Kerstin, additional, Pohlreich, David, additional, Lenain, Pascal, additional, Grasso, Mariella, additional, Caillot, Denis, additional, Einsele, Hermann, additional, Sengeloev, Henrik, additional, Meuleman, Nathalie, additional, Ciceri, Fabio, additional, Schönland, Stefan, additional, and Kröger, Nicolaus, additional

Published
2016
Full Text
View/download PDF

26. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.

Author

Bastidas, Adriana, de la Serna, Javier, El Idrissi, Mohamed, Oostvogels, Lidia, Quittet, Philippe, López-Jiménez, Javier, Vural, Filiz, Pohlreich, David, Zuckerman, Tsila, Issa, Nicolas C., Gaidano, Gianluca, Lee, Je-Jung, Abhyankar, Sunil, Solano, Carlos, Perez de Oteyza, Jaime, Satlin, Michael J., Schwartz, Stefan, Campins, Magda, Rocci, Alberto, and Vallejo Llamas, Carlos

Subjects
HERPES zoster vaccines, HERPES zoster, HEMATOPOIETIC stem cell transplantation, RECOMBINANT drugs, CLINICAL trials, HERPES zoster prevention, RESEARCH, IMMUNOCOMPROMISED patients, NEURALGIA, RESEARCH methodology, DISEASE incidence, IMMUNOMODULATORS, EVALUATION research, MEDICAL cooperation, INTRAMUSCULAR injections, AUTOGRAFTS, COMPARATIVE studies, RANDOMIZED controlled trials, BLIND experiment, HOSPITAL care, PROPORTIONAL hazards models, LONGITUDINAL method
Abstract

Importance: Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster.Objective: To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients.Design, Setting, and Participants: Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT.Interventions: Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n = 922) or placebo (n = 924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter.Main Outcomes and Measures: The primary end point was occurrence of confirmed herpes zoster cases.Results: Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P < .001), equivalent to 68.2% vaccine efficacy. Of 8 secondary end points, 3 showed significant reductions in incidence of postherpetic neuralgia (vaccine, n=1; placebo, n=9; IRR, 0.1; 95% CI, 0.00-0.78; P = .02) and of other prespecified herpes zoster-related complications (vaccine, n=3; placebo, n=13; IRR, 0.22; 95% CI, 0.04-0.81; P = .02) and in duration of severe worst herpes zoster-associated pain (vaccine, 892.0 days; placebo, 6275.0 days; hazard ratio, 0.62; 95% CI, 0.42-0.89; P = .01). Five secondary objectives were descriptive. Injection site reactions were recorded in 86% of vaccine and 10% of placebo recipients, of which pain was the most common, occurring in 84% of vaccine recipients (grade 3: 11%). Unsolicited and serious adverse events, potentially immune-mediated diseases, and underlying disease relapses were similar between groups at all time points.Conclusions and Relevance: Among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine compared with placebo significantly reduced the incidence of herpes zoster over a median follow-up of 21 months.Trial Registration: ClinicalTrials.gov Identifier: NCT01610414. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

27. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.

Author

UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - (SLuc) Service d'hématologie, Robinson, Stephen Paul, Boumendil, Ariane, Finel, Herve, Blaise, Didier, Poire, Xavier, Nicolas-Virelizier, Emmanuelle, Or, Reuven, Malladi, Ram, Corby, Anne, Fornecker, Luc, Caballero, Dolores, Pohlreich, David, Nagler, Arnon, Thieblemont, Catherine, Finke, Juergen, Bachy, Emmanuel, Vincent, Lionel, Schroyens, Wilfried, Schouten, Harry, Dreger, Peter, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - (SLuc) Service d'hématologie, Robinson, Stephen Paul, Boumendil, Ariane, Finel, Herve, Blaise, Didier, Poire, Xavier, Nicolas-Virelizier, Emmanuelle, Or, Reuven, Malladi, Ram, Corby, Anne, Fornecker, Luc, Caballero, Dolores, Pohlreich, David, Nagler, Arnon, Thieblemont, Catherine, Finke, Juergen, Bachy, Emmanuel, Vincent, Lionel, Schroyens, Wilfried, Schouten, Harry, and Dreger, Peter

Abstract

In the era of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large B-cell lymphoma has been challenged. We reviewed the outcome of standard salvage therapy with an autologous stem cell transplant (autoSCT) over the last two decades and the outcome of allogeneic SCT (alloSCT) in the most recent decade. AutoSCT recipients diagnosed between 1992 and 2002 (n=2737) were compared with those diagnosed between 2002 and 2010 (n=3980). Patients diagnosed after 2002 had a significantly lower non-relapse mortality (NRM) and relapse incidence (RI) and a superior PFS and overall survival (OS). A total of 4210 patients diagnosed between 2002 and 2010 underwent either an autoSCT or an alloSCT as their first transplant procedure. Two-hundred and thirty patients received an alloSCT (myeloablative (MACalloSCT) n=132, reduced intensity (RICalloSCT) n=98). The 4-year NRM rates were 7%, 20% and 27% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year RI was 45%, 40% and 38% for autoSCT, RICalloSCT and MACalloSCT, respectively (NS). The 4-year PFS were 48%, 52% and 35% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year OS was 60%, 52% and 38% for autoSCT, RIC alloSCT and MACalloSCT, respectively. After adjustment for confounding factors NRM was significantly worse for patients undergoing alloSCT whilst there was no difference in the RI.

Published
2016

29. Autologous hematopoietic stem cell transplantation in neuromyelitis optica : A registry study of the EBMT Autoimmune Diseases Working Party

Author

Greco, Raffaella, Bondanza, Attilio, Oliveira, Maria Carolina, Badoglio, Manuela, Burman, Joachim, Piehl, Fredrik, Hägglund, Hans, Krasulova, Eva, Simões, Belinda Pinto, Carlson, Kristina, Pohlreich, David, Labopin, Myriam, Saccardi, Riccardo, Comi, Giancarlo, Mancardi, Gian Luigi, Bacigalupo, Andrea, Ciceri, Fabio, Farge, Dominique, Greco, Raffaella, Bondanza, Attilio, Oliveira, Maria Carolina, Badoglio, Manuela, Burman, Joachim, Piehl, Fredrik, Hägglund, Hans, Krasulova, Eva, Simões, Belinda Pinto, Carlson, Kristina, Pohlreich, David, Labopin, Myriam, Saccardi, Riccardo, Comi, Giancarlo, Mancardi, Gian Luigi, Bacigalupo, Andrea, Ciceri, Fabio, and Farge, Dominique

Abstract

BACKGROUND: Neuromyelitis optica (NMO) is an inflammatory autoimmune disorder of the central nervous system, hallmarked by pathogenic anti-aquaporin 4 antibodies. NMO prognosis is worse compared with multiple sclerosis. OBJECTIVE: The European Group for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) conducted a retrospective survey to analyze disease outcome following autologous stem cell transplantation (ASCT). METHODS: This retrospective multicenter study assessed the efficacy and safety of ASCT in 16 patients suffering from refractory NMO reported to the EBMT registry between 2001 and 2011. RESULTS: Fifteen patients were successfully mobilized with cyclophosphamide (Cy) and G-CSF, one with G-CSF alone. All patients received an unmanipulated autologous peripheral blood stem cell graft, after conditioning with BEAM plus anti-thymocyte globulin (ATG, n = 9 patients), thiotepa-Cy (n = 3) or Cy (200 mg/kg) plus ATG (n = 4). After a median follow-up of 47 months, three of 16 cases were progression and treatment free, while in the remaining 13 patients further treatments were administered for disability progression or relapse after ASCT. Altogether, relapse-free survival at three and five years was 31% and 10%, respectively, while progression-free survival remained 48% at three and five years. CONCLUSIONS: In these NMO patients, highly resistant to conventional treatment, ASCT allows for temporary control of the disease, despite a tendency to progress or relapse in the long term.

Published
2015
Full Text
View/download PDF

31. High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study

Author

Avivi, Irit, primary, Arcaini, Luca, additional, Ferretti, Virginia, additional, Boumendil, Ariane, additional, Finel, Herve, additional, Pascutto, Cristiana, additional, Milone, Giuseppe, additional, Zaja, Francesco, additional, Liliana, Devizzi, additional, Musso, Maurizio, additional, Didier, Blaise, additional, Salles, Gilles, additional, Wattad, Mohammed, additional, Nicolas-Virelizier, Emmanuelle, additional, Gramatzki, Martin, additional, Bourhis, Jean-Henri, additional, Caillot, Denis, additional, Haenel, Shannon, additional, Haenel, Anette, additional, Held, Gerhard, additional, Thieblemont, Catherine, additional, Jindra, Pavel, additional, Pohlreich, David, additional, Guilhot, François, additional, Bornhaeuser, Martin, additional, Ljungman, Per T., additional, Scheid, Christof, additional, Ifrah, Norbert, additional, Berthou, Christian, additional, Dreger, Peter, additional, Montoto, Silvia, additional, and Conconi, Annarita, additional

Published
2014
Full Text
View/download PDF

32. Autologous Stem Cell Transplantation for Primary Mediastinal B Cell Lymphoma in the Rituximab Era: A Retrospective Study By the EBMT Lymphoma Working Party

Author

Avivi, Irit, primary, Boumendil, Ariane, additional, Hervé Finel, Hervé, additional, Nagler, Arnon, additional, Bothello, Aïda Sousa, additional, Santasusana, Josep Maria Ribera, additional, Vandenberghe, Elisabeth A., additional, Afanasyev, Boris, additional, Bordessoule, Dominique, additional, Moraleda, José Maria, additional, Conde, Eulogio, additional, Pohlreich, David, additional, and Dreger, Peter, additional

Published
2014
Full Text
View/download PDF

33. Non Interventional Prospective Clinical Study on Peripheral Blood Stem Cell Mobilization in Patients with Relapsed Lymphomas

Author

van Gorkom, Gwendolyn, primary, Finel, Herve, additional, Giebel, Sebastian, additional, Pohlreich, David, additional, Shimoni, Avichai, additional, Ringhoffer, Mark, additional, Sucak, Gulsan Ayhan, additional, Schaap, Nicolaas PM, additional, Dreger, Peter, additional, Sureda, Anna, additional, and Schouten, Harry C, additional

Published
2014
Full Text
View/download PDF

34. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas.

Author

Gorkom, Gwendolyn, Finel, Herve, Giebel, Sebastian, Pohlreich, David, Shimoni, Avichai, Ringhoffer, Mark, Sucak, Gülsan, Schaap, Nicolaas, Dreger, Peter, Sureda, Anna, and Schouten, Harry C.

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) to rescue hematopoiesis is considered standard care for patients with a relapsed chemosensitive lymphoma, but diagnosis of lymphoma has been a risk factor for poor mobilization in several studies. The aim of this prospective noninterventional clinical audit was to review the mobilization strategies used by EBMT centers in relapsed lymphoma and to evaluate their efficacy. Between 2010 and 2014, 275 patients with relapsed lymphoma from 30 EBMT centers were prospectively registered. Almost all patients were mobilized with chemotherapy plus G-CSF (96%), but there was a large variation in chemotherapy schedules. Thirty (11%) of them were poor mobilizers (<2 × 106 CD 34+ cells/kg body weight) at the first mobilization. Poor mobilization was not associated with gender, age, bone marrow involvement at diagnosis, primary diagnosis, number of previous chemotherapy lines, previous radiotherapy or mobilization with G-CSF alone. The use of high dose cyclophosphamide alone was associated with mobilization failure ( P = 0.0006), whereas the use of a platinum-containing regimen was associated with a good mobilization outcome ( P = 0.013). Because failure rate is low, we can conclude from this study that PBSC mobilization failure in relapsed lymphomas is not an important problem in the EBMT centers. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

35. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party

Author

Greco, Raffaella, primary, Bondanza, Attilio, additional, Oliveira, Maria Carolina, additional, Badoglio, Manuela, additional, Burman, Joachim, additional, Piehl, Fredrik, additional, Hagglund, Hans, additional, Krasulova, Eva, additional, Simões, Belinda Pinto, additional, Carlson, Kristina, additional, Pohlreich, David, additional, Labopin, Myriam, additional, Saccardi, Riccardo, additional, Comi, Giancarlo, additional, Mancardi, Gian Luigi, additional, Bacigalupo, Andrea, additional, Ciceri, Fabio, additional, and Farge, Dominique, additional

Published
2014
Full Text
View/download PDF

37. The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party

Author

El-Najjar, Inas, primary, Boumendil, Ariane, additional, Luan, Jian Jian, additional, Thieblemont, Catherine, additional, Blaise, Didier, additional, Thomson, Kirsty, additional, Le Gouill, Steven, additional, Lissandre, Severine, additional, Rambaldi, Alessandro, additional, Jouet, Jean-Pierre, additional, Biron, Pierre, additional, Martelli, Massimo Fabrizio, additional, Tilly, Herve, additional, Pohlreich, David, additional, Pfreundschuh, Michael, additional, Cordonnier, Catherine, additional, Crawley, Charles, additional, Cahn, Jean-Yves, additional, Paul Vernant, Jean, additional, Gribben, John G., additional, Cook, Gordon, additional, Russell, Nigel H., additional, Ferrant, Augustin, additional, Montoto, Silvia, additional, and Dreger, Peter, additional

Published
2011
Full Text
View/download PDF

38. Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study

Author

Daikeler, Thomas, primary, Labopin, Myriam, additional, di Gioia, Massimo, additional, Abinun, Mario, additional, Alexander, Tobias, additional, Miniati, Irene, additional, Gualandi, Francesca, additional, Fassas, Athanasios, additional, Martin, Thierry, additional, Schwarze, Carl-Philipp, additional, Wulffraat, Nico, additional, Buch, Maya, additional, Sampol, Antonia, additional, Carreras, Enric, additional, Dubois, Benedict, additional, Gruhn, Bernd, additional, Güngör, Tayfun, additional, Pohlreich, David, additional, Schuerwegh, Annemie, additional, Snarsky, Emilian, additional, Snowden, John, additional, Veys, Paul, additional, Fasth, Anders, additional, Lenhoff, Stig, additional, Messina, Chiara, additional, Voswinkel, Jan, additional, Badoglio, Manuela, additional, Henes, Jörg, additional, Launay, David, additional, Tyndall, Alan, additional, Gluckman, Eliane, additional, and Farge, Dominique, additional

Published
2010
Full Text
View/download PDF

40. Management of Relapsed/Refractory Hodgkin Lymphomas After ASCT in Czech Republic.

Author

Mocikova, Heidi, primary, Pytlik, Robert, additional, Raida, Ludek, additional, Zak, Pavel, additional, Markova, Jana, additional, Kral, Zdenek, additional, Steinerova, Katerina, additional, Valkova, Veronika, additional, Trnkova, Marie, additional, Vackova, Blanka, additional, Pohlreich, David, additional, Faber, Edgar, additional, Indrak, Karel, additional, Belada, David, additional, Kozak, Tomas, additional, Mayer, Jiri, additional, Vitek, Antonin, additional, Koza, Vladimir, additional, and Trneny, Marek, additional

Published
2009
Full Text
View/download PDF

45. Elevated Numbers of Immature/Transitional CD21− B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients with Active Chronic Graft-versus-Host Disease

Author

Greinix, Hildegard T., Pohlreich, David, Kouba, Michal, Körmöczi, Ulrike, Lohmann, Imke, Feldmann, Karin, Zielinski, Christoph, and Pickl, Winfried F.

Subjects
*B cells, *LYMPHOCYTES, *CELL transplantation, *CELLULAR therapy
Abstract

Abstract: Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT) and a leading cause of non-relapse mortality (NRM). Currently, biology-based markers are lacking both for diagnosis and for monitoring the activity of cGVHD. Seventy patients who received HSCT were enrolled in a pilot study, including 21 without cGVHD and 49 with active or resolved cGVHD. Evaluations were comprised of clinical parameters including cGVHD severity and infections. Peripheral blood cells were analyzed by multi-parameter flow cytometry. The CD19+ B cell compartment was further subdivided by staining for surface IgD, CD21 and CD27. No significant differences in absolute B, T, and natural killer (NK) cell numbers were observed between the groups with and without cGVHD. However, elevated numbers (>15% of B lymphocytes) of immature/transitional CD19+/CD21- B cells were associated with the occurrence of severe infections (P = .003). Most significantly, all patients with active cGVHD and elevated numbers of CD19+/CD21- B lymphocytes experienced severe infections (P = .00016). The numbers of both non-class-switched and class-switched memory B cells were significantly lower in patients with active cGVHD when compared to patients who never experienced cGVHD (P = .002 and P = .001). Perturbation of circulating B lymphocyte compartments may serve as a novel biomarker for monitoring cGVHD activity and its impact on the immune system. A prospective study on unselected patients assessed serially for B cell reconstitution after HSCT is warranted. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

46. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party

Author

Daikeler, Thomas, Labopin, Myriam, Di Gioia, Massimo, Abinun, Mario, Alexander, Tobias, Miniati, Irene, Gualandi, Francesca, Fassas, Athanasios, Martin, Thierry, Schwarze, Carl Philipp, Wulffraat, Nico, Buch, Maya, Sampol, Antonia, Carreras, Enric, Dubois, Benedicte, Gruhn, Bernd, Güngör, Tayfun, Pohlreich, David, Schuerwegh, Annemie, Snarski, Emilian, Snowden, John, Veys, Paul, Fasth, Anders, Lenhoff, Stig, Messina, Chiara, Voswinkel, Jan, Badoglio, Manuela, Henes, Jörg, Launay, David, Tyndall, Alan, Gluckman, Eliane, and Farge, Dominique

Abstract

To specify the incidence and risk factors for secondary autoimmune diseases (ADs) after HSCT for a primary AD, we retrospectively analyzed AD patients treated by HSCT reported to EBMT from 1995 to 2009 with at least 1 secondary AD (cases) and those without (controls). After autologous HSCT, 29 of 347 patients developed at least 1 secondary AD within 21.9 (0.6-49) months and after allogeneic HSCT, 3 of 16 patients. The observed secondary ADs included: autoimmune hemolytic anemia (n = 3), acquired hemophilia (n = 3), autoimmune thrombocytopenia (n = 3), antiphospholipid syndrome (n = 2), thyroiditis (n = 12), blocking thyroid-stimulating hormone receptor antibody (n = 1), Graves disease (n = 2), myasthenia gravis (n = 1), rheumatoid arthritis (n = 2), sarcoidosis (n = 2), vasculitis (n = 1), psoriasis (n = 1), and psoriatic arthritis (n = 1). After autologous HSCT for primary AD, the cumulative incidence of secondary AD was 9.8% ± 2% at 5 years. Lupus erythematosus as primary AD, and antithymocyte globulin use plus CD34+graft selection were important risk factors for secondary AD by multivariate analysis. With a median follow-up of 6.2 (0.54-11) years after autologous HSCT, 26 of 29 patients with secondary AD were alive, 2 died during their secondary AD (antiphospholipid syndrome, hemophilia), and 1 death was HSCT-related. This European multicenter study underlines the need for careful management and follow-up for secondary AD after HSCT.

Published
2011
Full Text
View/download PDF

50. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: A retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO

Author

Virginia Valeria Ferretti, Christof Scheid, Frank Kroschinsky, Ariane Boumendil, Gerhard Held, Denis Caillot, Björn E. Wahlin, Norbert Ifrah, Jean Bourhis, Mohammed Wattad, Maurizio Musso, David Pohlreich, Catherine Thieblemont, Peter Dreger, Pavel Jindra, Emmanuelle Nicolas-Virelizier, Anette Haenel, Irit Avivi, Martin Gramatzki, Blaise Didier, Silvia Montoto, Giuseppe Milone, Devizzi Liliana, Christian Berthou, Luca Arcaini, François Guilhot, Emmanuel Bachy, Francesco Zaja, Annarita Conconi, Herve Finel, Avivi, Irit, Arcaini, Luca, Ferretti, Virginia V., Boumendil, Ariane, Finel, Hervé, Milone, Giuseppe, Zaja, Francesco, Liliana, Devizzi, Musso, Maurizio, Didier, Blaise, Bachy, Emmanuel, Wattad, Mohammed, Nicolas-Virelizier, Emmanuelle, Gramatzki, Martin, Bourhis, Jean-Henri, Caillot, Deni, Haenel, Anette, Held, Gerhard, Thieblemont, Catherine, Jindra, Pavel, Pohlreich, David, Guilhot, Françoi, Kroschinsky, Frank, Wahlin, Björn, Scheid, Christof, Ifrah, Norbert, Berthou, Christian, Dreger, Peter, Montoto, Silvia, Conconi, Annarita, Tel Aviv Sourasky Medical Center [Te Aviv], Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Service de Réanimation Médicale [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Lymphoma Working Party, Paris (EBMT), Oncohematology Unit, Oncology Department La Maddalena, Centre Léon Bérard [Lyon], 2nd Medical Department, University Hospital Schleswig-Holstein Campus Kiel, Division of Stem Cell Transplantation and, Institut Gustave Roussy (IGR), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Instituto de Pesquisas Meteorológicas (IPMet), Universidade Estadual Paulista Júlio de Mesquita Filho = São Paulo State University (UNESP), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Department of Hematology and Oncology [Pilsen, Czech Republic], Charles University Hospital Pilsen, Charles University Hospital, CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department I of Internal Medicine, University of Cologne, Hematology Department, Université d'Angers (UA), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHRU Brest - Service d'Hématologie (CHU-Brest-Hemato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Department of Medicine V, Universität Heidelberg [Heidelberg], AOU Maggiore della Carità, Division of Hematology, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Universidade Estadual Paulista Júlio de Mesquita Filho [São José do Rio Preto] (UNESP), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), and Université de Brest (UBO)

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Autologous transplant, [SDV]Life Sciences [q-bio], Transplantation, Autologous, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, Chemoimmunotherapy, Marginal zone lymphoma, Mucosa-associated lymphoid tissue lymphoma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Cumulative incidence, Treatment Failure, Retrospective Studies, business.industry, Hematopoietic Stem Cell Transplantation, MALT lymphoma, Lymphoma, B-Cell, Marginal Zone, Hematology, Middle Aged, Prognosis, medicine.disease, Survival Analysis, 3. Good health, Lymphoma, Transplantation, Regimen, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Rituximab, business, Follow-Up Studies, 030215 immunology, medicine.drug
Abstract

IF 5.128; International audience; The role of autologous stem cell transplantation (ASCT) in patients with marginal zone lymphoma (MZL) is debatable. This study investigated the outcome and prognostic factors affecting the outcome of patients undergoing ASCT for MZL. Eligible patients had non‐transformed nodal, extra‐nodal (MALT) or splenic MZL (SMZL), aged ≥18 years, who underwent a first ASCT between1994 and 2013 and were reported to the European Society for Blood and Marrow Transplantation, Fondazione Italiana Linfomi or Gruppo Italiano Trapianto Di Midollo Osseo registries. The study included 199 patients, [111 MALT lymphoma, 55 nodal MZL (NMZL) and 33 SMZL]. Median age at transplantation was 56 years. The median number of prior therapies was 2 (range 1–8), including rituximab in 71%. 95% had chemosensitive disease. 89% received a chemotherapy‐based high‐dose regimen. There were no significant differences in patient and transplant characteristics between the 3 histological subtypes except for a lower percentage of patients previously treated with rituximab in the MALT sub‐group and more transplants performed in recent years in the other sub‐groups. After a median follow‐up of 5 years, 5‐year cumulative incidence of relapse/progression and non‐relapse mortality were 38% and 9%, respectively. Five‐year event‐free survival (EFS) and overall survival (OS) were 53% and 73%, respectively. Five‐year cumulative incidence of second malignancies was 6%. Multivariate analysis revealed age ≥65 years was associated with a shorter EFS and OS. In addition, patients with SMZL had a shorter OS than those with MALT. ASCT may provide clinical benefit in MZL patients who have failed multiple lines of chemoimmunotherapy.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results